A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.

The early stages of any new, clinically impactful drug put pressure on benefit leaders. While research evolves at a pace that keeps health care professionals on their toes, benefit leaders must make ...

GLP-1 weight-loss drugs might be providing a quick fix to a growing number of users but there are many unknowns as to the real or potential hit on packaged foods manufacturers in both the short and ...

Glucagon-like peptide-1, or “GLP-1” drugs, such as Ozempic® and Mounjaro®, have exploded in popularity in the United States for weight management and the treatment of obesity. However, GLP-1 drugs ...

After selling his previous firm, The Medicines Company, to Novartis for $9.7 billion, Clive Meanwell is on to his next challenge: a start-up called Metsera that aims to expand on the success of ...

Imagine if losing weight were as simple as swallowing a daily pill-no needles, no injections and no anxiety. If you're among the 25 percent of adults who fear needles, per Harvard Health, or if ...

Add Yahoo as a preferred source to see more of our stories on Google. It was all in support of the newly launched WeightWatchers GLP-1 Program, which offers guidance to those using medication, rather ...

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is ...